ESMO 2026 MOIO: Extending Immunotherapy To Every 12 Weeks In Responders Not Supported By Interim Analysis

Can Immunotherapy Be Spaced Out? What The MOIO Interim Analysis Says About Efficacy, Survival And Safety

The interim analysis of the MOIO trial, presented on October 26, 2026 in Presidential Symposium III at the ESMO Congress in Madrid, found that giving an immune checkpoint inhibitor every 12 weeks, instead of the standard schedule, did not meet the non-inferiority margin for progression-free survival in patients with advanced solid tumors who had responded to the first 6 months of standard immunotherapy (OncoDaily report). For overall survival, a secondary endpoint, a signal against the every-12-weeks arm was seen; however, this is an interim analysis. The design was described in the 2023 protocol paper. We have previously covered related questions in our articles on treatment duration, the dosing approach and why more is not always better.

Why does this matter?

PD-1 and PD-L1 inhibitors (pembrolizumab, nivolumab, atezolizumab and others) form the backbone of immunotherapy and are standard treatment in many cancers. In some responding patients the response lasts for months after treatment is stopped, and survival plateaus have been reported in melanoma, non-small cell lung cancer and kidney cancer (5-year survival with pembrolizumab). How long, and how often, treatment should continue in a responding patient remains unclear (long-term effects).

According to the protocol paper, pharmacokinetic studies have not shown a clear dose effect for these drugs, and the optimal dose is unknown. The long duration of target engagement (how long cancer drugs stay in the body) makes less frequent dosing theoretically attractive. If confirmed, spacing out treatment could reduce hospital visits, immune-related side effects and cost.

MOIO tests this question not in a single tumor type but across responding advanced solid tumors, with randomization and a prespecified non-inferiority margin. That makes it one of the most direct pieces of evidence to date for routine practice.

Can immunotherapy be given every 12 weeks?

In responding patients, extending immunotherapy to every 12 weeks did not meet the non-inferiority margin for progression-free survival in the MOIO interim analysis (HR 1.35; 95% CI 0.90–2.00; margin 1.30), and a concerning signal appeared for overall survival. The results therefore do not support routine 12-week extension; the dosing interval should be decided together with your oncologist.

How was the MOIO trial designed?

Results

Progression-free survival (primary endpoint)

At the interim analysis, median progression-free survival was 25.0 months in the standard arm and 21.9 months in the every-12-weeks arm, an absolute difference of about 3.1 months (HR 1.35). Because the confidence interval includes both 1 and the 1.30 margin, the result does not prove that every-12-weeks dosing is worse, but it also cannot show that it is not worse than the standard schedule. That distinction matters when interpreting the result.

Overall survival (secondary endpoint)

The risk of loss of life was 2-fold higher in the every-12-weeks arm than in the standard arm (HR 2.00; 95% CI 1.10–3.90; reported p=0.0143). Because per-arm median overall survival and numbers of events were not reported, the absolute difference is unknown. The signal comes from a secondary endpoint, an interim analysis, short follow-up of 18.6 months and a wide confidence interval; still, it points in the same direction as progression-free survival and should be watched closely.

Progression-free survival by tumor type (subgroups)

Subgroup estimates are imprecise and patient numbers were not reported, so they do not show that extending the interval is safe in any particular tumor type. Tumors included in the trial cover lung, urothelial, kidney and head and neck cancers.

Safety

Grade 3–4 immune-related adverse events occurred in 10.5% of the standard arm and 9.5% of the every-12-weeks arm; serious adverse events were 26.3% and 25.0%. These rates do not show that less frequent dosing clearly lowers the side-effect burden, but they do not prove safety equivalence either. Fewer administrations should not be assumed to bring a clinical safety benefit (recognizing immune-related adverse events (Türkçe), managing side effects).

How should the results be read?

Strengths

• An independent, academic (UNICANCER) trial that asks a question from clinical practice rather than one driven by a sponsor.
• Randomized phase 3 design with a prespecified non-inferiority margin (HR 1.30); primary analysis in two analysis populations.
• Close to real life because it covers different tumor types, treatment lines and drugs.
• Stratified by complete / partial response, PD-1 / PD-L1, tumor type and line of treatment.

Points to watch

• Interim analysis and short follow-up: Median follow-up 18.6 months; about 53% (340) of the 646 planned patients were randomized, and it was not reported that all 498 events had been reached.
• Heterogeneous population: Different tumor types, drugs and lines are pooled; subgroup estimates are wide and exploratory.
• Open-label design: Patients and physicians know the arm, which can influence follow-up and assessment.
• Overall survival signal: A secondary endpoint at an interim analysis; we did not see per-arm medians or event counts. Still, it is not a signal to be ignored.
• Missing results: Cost-effectiveness, duration of response and other secondary endpoints were not reported in the sources we found; the full presentation and a peer-reviewed publication are awaited.

What does this mean in practice?

• Routine practice does not change: In responding patients, treatment should continue on the licensed schedule; a routine 12-week extension cannot be recommended.
• Frequency and duration are separate questions: MOIO tested lengthening the interval of the same dose, not stopping treatment. How long to treat is a separate research question.
• Combinations need separate consideration: How these results apply to combination regimens such as nivolumab plus ipilimumab is unclear.
• Who can safely receive less treatment is still open: Biomarker-guided approaches (ctDNA-guided treatment) may be better suited to answering this.

Practical tips for patients and families

• Do not stretch your treatment interval or skip cycles without asking your doctor; in this trial the interval was extended under team supervision and within a protocol.
• Even if you have responded, ask your oncologist how long your treatment will last and how often it will be given.
• If the frequency of hospital visits, travel or cost is a problem, tell your team openly; options can be considered together.
• Seek help promptly for diarrhea, skin rash and lasting skin problems, shortness of breath, extreme fatigue, excessive thirst and frequent urination (diabetes) or kidney symptoms.
• Ask whether a suitable clinical trial exists (what is a clinical trial?, who can take part in Türkiye?).
• Do not hesitate to get a second opinion before deciding; results from a trial cannot be applied unchanged to every patient or every tumor type.

Frequently Asked Questions

What does the MOIO trial investigate?

MOIO is a randomized phase 3 trial testing whether giving the same dose of the same drug every 12 weeks is worse, in terms of progression-free survival, than the standard schedule in patients with advanced solid tumors who responded to the first 6 months of standard immunotherapy.

What did MOIO find?

At the interim analysis, non-inferiority was not met: median progression-free survival was 25.0 months in the standard arm and 21.9 months in the every-12-weeks arm (HR 1.35; 95% CI 0.90–2.00). For overall survival, a secondary endpoint, an HR of 2.00 (95% CI 1.10–3.90) pointed against the every-12-weeks arm.

Does this mean I should stop immunotherapy?

No. The trial tested lengthening the interval of the same dose, not stopping treatment. Do not change the frequency or duration of your treatment on your own; this decision should be made together with your oncologist.

Can dosing every 12 weeks be used in Türkiye?

Licensed and reimbursed immunotherapy regimens are defined by the intervals in the label; to our knowledge, a 12-week extension falls outside them. The MOIO results do not support routine use of this approach either.

Glossary

Non-inferiority

A trial design that aims to show a new or less frequent approach is not worse than standard treatment by more than a prespecified margin.

Immune checkpoint inhibitor

A drug that blocks proteins such as PD-1 or PD-L1 so that the immune system becomes active against cancer cells.

Progression-free survival (PFS)

The time from randomization until disease progression or loss of life from any cause.

Overall survival

The time patients remain alive from randomization.

Hazard ratio (HR)

The ratio of the rate of an event (progression or loss of life) between two arms; above 1 means a higher risk than the comparison arm.

Modified ITT

An analysis population that includes randomized patients who meet prespecified conditions.

Immune-related adverse event (irAE)

A side effect in organs caused by immunotherapy activating the immune system (colitis, thyroid, skin and others).

Open-label

A trial design in which patients and physicians know which treatment is given.